{"id":"myfortic-plus-low-dose-steroid","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)"},{"rate":"20-30","effect":"Infection (bacterial, viral, fungal)"},{"rate":"15-25","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"10-15","effect":"Hypertension"},{"rate":"10-15","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Tremor, headache"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolate sodium is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for guanine nucleotide synthesis in lymphocytes. This preferentially depletes guanine nucleotides in T and B cells, inhibiting their proliferation. The addition of low-dose corticosteroids enhances immunosuppression through glucocorticoid receptor-mediated suppression of cytokine production and immune cell activation.","oneSentence":"Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection, while the steroid provides additional anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:18.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)"}]},"trialDetails":[{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT01282073","phase":"PHASE3","title":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2011-03","conditions":"Glomerulonephritis, Membranous","enrollment":43},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT05789017","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT04936282","phase":"PHASE4","title":"Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)","status":"UNKNOWN","sponsor":"Fundación Canaria de Investigación Sanitaria","startDate":"2022-07-05","conditions":"Kidney Transplant Failure and Rejection","enrollment":80},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT05423496","phase":"NA","title":"KidneyCare Immuno-optimization in Renal Allografts (KIRA)","status":"WITHDRAWN","sponsor":"CareDx","startDate":"2022-08","conditions":"Kidney Transplant, Immunosuppression, Allograft","enrollment":""},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT05415579","phase":"","title":"Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)","status":"NOT_YET_RECRUITING","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2022-06-20","conditions":"Demyelinating Diseases of the Central Nervous System (DDC)","enrollment":2000},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT03492255","phase":"NA","title":"CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid","status":"TERMINATED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-04-12","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":49},{"nctId":"NCT04744623","phase":"PHASE2, PHASE3","title":"Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-09-30","conditions":"Benign Mucous Membrane Pemphigoid","enrollment":10},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT04438603","phase":"","title":"The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-10-01","conditions":"IgA Nephropathy","enrollment":180},{"nctId":"NCT01095172","phase":"PHASE4","title":"RituxiMab INDuction in Renal Transplantation","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2010-11","conditions":"Function of Renal Transplant","enrollment":100},{"nctId":"NCT03170323","phase":"PHASE4","title":"Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-07-01","conditions":"Idiopathic Membranous Nephropathy","enrollment":128},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01185197","phase":"PHASE4","title":"Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-09","conditions":"Nephrosis, Lipoid","enrollment":20},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01197040","phase":"PHASE3","title":"Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-10","conditions":"Nephrotic Syndrome","enrollment":117},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT00596947","phase":"PHASE4","title":"Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2005-10","conditions":"Transplants and Implants","enrollment":18},{"nctId":"NCT00075478","phase":"PHASE3","title":"Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT00551291","phase":"PHASE2","title":"A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT02683291","phase":"PHASE4","title":"Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients","status":"COMPLETED","sponsor":"Associação Médico Espírita de Botucatu","startDate":"2014-01","conditions":"Disorder Related to Renal Transplantation, Cytomegalovirus Infections","enrollment":48},{"nctId":"NCT01817322","phase":"PHASE4","title":"Kidney Graft Function Under the Immunosuppression Strategies","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Chronic Renal Disease","enrollment":140},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01346085","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2006-10","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT02095418","phase":"NA","title":"Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-02","conditions":"Diabetes","enrollment":152},{"nctId":"NCT01706471","phase":"PHASE4","title":"Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-06","conditions":"Planned Kidney Transplantation","enrollment":60},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2},{"nctId":"NCT00423098","phase":"PHASE2","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":"Lupus Nephritis","enrollment":81},{"nctId":"NCT00251004","phase":"PHASE3","title":"Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Kidney Transplantation, Graft Rejection","enrollment":833},{"nctId":"NCT00956059","phase":"NA","title":"Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis","status":"UNKNOWN","sponsor":"Xi'an Jiaotong University","startDate":"2009-09","conditions":"Focal Segmental Glomerulosclerosis","enrollment":40},{"nctId":"NCT00912678","phase":"PHASE4","title":"Minimizing Immunosuppression in Old for Old Kidney Transplantation","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2002-03","conditions":"Kidney Transplantation","enrollment":90},{"nctId":"NCT00695344","phase":"PHASE4","title":"Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant","status":"UNKNOWN","sponsor":"Fundacion Investigacion y Desarrollo","startDate":"2006-01","conditions":"Cardiac Transplant","enrollment":52},{"nctId":"NCT00309270","phase":"PHASE2","title":"Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2003-02","conditions":"Kidney Transplant","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mycophenolate sodium"],"phase":"marketed","status":"active","brandName":"Myfortic plus low-dose steroid","genericName":"Myfortic plus low-dose steroid","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection in transplant recipients. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}